Enhance the awareness of neuromyelitis optica-related optic neuritis to improve early diagnosis and treatment outcomes
10.3760/cma.j.issn.1005-1015.2019.03.001
- VernacularTitle:增强对视神经脊髓炎相关性视神经炎的认识,提高早期正确诊断及治疗水平
- Author:
Shihui WEI
1
;
Honglu SONG
Author Information
1. 解放军总医院第一医学中心眼科
- Keywords:
Neuromyelitis optica;
Optic neuritis;
Aquaporin 4;
Editorial
- From:
Chinese Journal of Ocular Fundus Diseases
2019;35(3):215-218
- CountryChina
- Language:Chinese
-
Abstract:
Neuromyelitis optica-related optic neuritis (NMO-ON) is a kind of severe optic nerve disease,which always leads to replase,poor prognosis,and even blindness.Aquaporin 4 antibody (AQP4-IgG) is the main diagnostic biomarker for neuromyelitis optica with high specificity.Serum myelin oligodendrocyte glycoprotein antibody (MOG-IgG) is helpful for the diagnosis of AQP4-IgG negative patients.The study of biomarkers is helpful to deeply understand the pathogenesis of NMO-ON,help the diagnosis of the disease,and finally make precise treatment.Orbital MRI can help to differentiate MOG-IgG positive from AQP4-IgG positive neuromyelitis optica and optic neuritis,which is very important for the diagnosis of NMO-ON.At present,the standardized treatment of NMO-ON can be divided into two clinical stages:acute stage and remission stage.Corticosteroids and plasma exchange are the main treatments in acute stage,aiming at alleviating acute inflammatory reaction and improving prognosis.Immunosuppressive agents and biological agents are the main treatments in remission stage,aiming at preventing or reducing recurrence.With the development of the diagnosis and treatment of NMO-ON,we find that it is more and more important to strengthen the construction of neuro-ophthalmology team in China,establish clinical epidemiological database of NMO-ON,and carry out multi-centre,large-sample,prospective clinical control studies in China to provide evidence-based medicine for Chinese people.In addition,we need to strengthen efforts to establish and improve the diagnostic criteria for NMO-ON and the promotion of diagnostic and therapeutic criteria,and strive to improve the clinical diagnosis and treatment level of NMO-ON in China.
